Abstract
For the last 60 years warfarin has been the cornerstone for chronic anticoagulation in prevention of ischemic strokes and systemic embolization. Warfarin therapy has several limitations including frequent monitoring and various food and significant drug interactions, which make it a less than ideal chronic oral anticoagulant. The continued search for safe, effective, medications with predictable pharmacokinetic profiles has led to newer alternatives. Dabigatran is a potent reversible, competitive direct thrombin inhibitor which is available as the prodrug, Dabigatran etexilate. It was first approved in Europe and recently in October 2010, the US food and drug administration (FDA) has approved the use of this novel oral anticoagulation for prevention of stroke in those with non valvular atrial fibrillation. This review will cover the chemical structure, mechanism of action, pharmacokinetic profile, clinical trials, dosage, clinical implication and adverse effects of dabigatran.
Keywords: Anticoagulation, atrial fibrillation, BISTRO trial, chemical structure, dabigatran, diract thrombin inhibitors, PETRO trial, pharmacodynamics, pharmacokinetics, Re-Ly trial, RECOVER trial, stroke warfarin
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Dabigatran - A New Chapter in Anticoagulation
Volume: 10 Issue: 2
Author(s): Shameer Ahmed, Vadim Levin, Robert Malacoff and Matthew W. Martinez
Affiliation:
Keywords: Anticoagulation, atrial fibrillation, BISTRO trial, chemical structure, dabigatran, diract thrombin inhibitors, PETRO trial, pharmacodynamics, pharmacokinetics, Re-Ly trial, RECOVER trial, stroke warfarin
Abstract: For the last 60 years warfarin has been the cornerstone for chronic anticoagulation in prevention of ischemic strokes and systemic embolization. Warfarin therapy has several limitations including frequent monitoring and various food and significant drug interactions, which make it a less than ideal chronic oral anticoagulant. The continued search for safe, effective, medications with predictable pharmacokinetic profiles has led to newer alternatives. Dabigatran is a potent reversible, competitive direct thrombin inhibitor which is available as the prodrug, Dabigatran etexilate. It was first approved in Europe and recently in October 2010, the US food and drug administration (FDA) has approved the use of this novel oral anticoagulation for prevention of stroke in those with non valvular atrial fibrillation. This review will cover the chemical structure, mechanism of action, pharmacokinetic profile, clinical trials, dosage, clinical implication and adverse effects of dabigatran.
Export Options
About this article
Cite this article as:
Ahmed Shameer, Levin Vadim, Malacoff Robert and W. Martinez Matthew, Dabigatran - A New Chapter in Anticoagulation, Cardiovascular & Hematological Agents in Medicinal Chemistry 2012; 10 (2) . https://dx.doi.org/10.2174/187152512800388911
DOI https://dx.doi.org/10.2174/187152512800388911 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Hot Topic:Human Pluripotent Stem Cells in Regenerative and Personalized Medicine)
Current Molecular Medicine A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant Patients
Current Drug Safety Editorial: Current Strategies in Targeting Brain Disorders
CNS & Neurological Disorders - Drug Targets DNA and RNA Aptamers as Modulators of Protein Function
Medicinal Chemistry Transglutaminase-Catalyzed Crosslinking in Neurological Disease: From Experimental Evidence to Therapeutic Inhibition
CNS & Neurological Disorders - Drug Targets Buckwheat: A Useful Food and Its Effects on Human Health
Current Nutrition & Food Science Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration
Current Genomics Nifedipine Inhibits the Progression of An Experimentally Induced Cerebral Aneurysm in Rats with Associated Down-Regulation of NF-Kappa B Transcriptional Activity
Current Neurovascular Research Polymeric Materials and Formulation Technologies for Modified-Release Tablet Development
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease)
Reviews on Recent Clinical Trials Genetics in Anti-Platelet Treatment
Current Pharmaceutical Design Platelet Resistance to Antiplatelet Drugs
Recent Patents on Cardiovascular Drug Discovery Fas Ligand Gene Therapy for Vascular Intimal Hyperplasia
Current Gene Therapy An Efficient Synthesis of 2-Substituted Quinazolin-4(3H)-ones by Using Recyclable Wang Resin Supported Sulfonic Acid Catalyst
Letters in Organic Chemistry Thyroid Dysfunction in Pregnant Women with Gestational Diabetes Mellitus
Current Diabetes Reviews Patterns of Gray and White Matter Changes in Individuals at Risk for Alzheimer’s Disease
Current Alzheimer Research Recent Advances in Transition Metal Free Synthetic Protocols for Quinoline Derivatives
Current Organic Chemistry Development of Novel Therapeutic Strategies for Lung Cancer: Targeting the Cholinergic System
Current Medicinal Chemistry Role of Platelet Function Testing in Clinical Practice: Current Concepts and Future Perspectives
Current Drug Targets Hyperhomocysteinemia and Cardiovascular Risk: Effect of Vitamin Supplementation in Risk Reduction
Current Clinical Pharmacology